6月25日，Twist Bioscience盘中上涨6.12%，报93.57美元/股，成交额2344.15万美元，股价已突破此前Canaccord Genuity给予的90美元目标价。
消息面上，公司此前因提交至多2亿美元普通股货架注册声明引发稀释担忧，股价一度回调逾5%。随后Canaccord Genuity给予买入评级及90美元目标价（显著高于市场共识73.12美元），叠加多家投行此前上调评级，市场情绪快速修复。公司Q3收入指引1.14亿至1.15亿美元超市场预期，并预计本财年第四季度实现调整后EBITDA盈亏平衡，基本面改善预期持续支撑股价走高。
Twist Bioscience是一家合成生物学平台公司，开发基于硅芯片的DNA合成技术，服务于医疗健康、食品农业、工业化学品及数据存储等领域。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.